Orthofix Investor Presentation Deck
IN
Meaningful Revenue
& Cost Synergies
✓
Est. Revenue Synergies: >$25M*
Est. Cost Synergies:~$50M**
Revenue Risk to Manage:
~$20M***
Working Capital & Capex
Synergies
Merger Highlights
88
Complementary
Portfolios
#1 Prescribed bone
growth stimulator
portfolio in the U.S.
Broadest advanced DBM
portfolio, market leading cellular
allograft, and comprehensive
line of synthetics
Next generation differentiated
artificial cervical disc
Å
Broader
Commercial Reach
✓ Accelerated adoption of
differentiated technologies
✓ Sustainable growth & value
creation
✓ Strengthened U.S. and
international sales channels
✓ Rapid product innovation
driving market-share taking
*Revenue synergies of $25M expected by 2025
**Cost synergies of ~$50M expected by 2025 w ith incremental opportunity to reduce stock-based compensation expense
"Based on due diligence, including revenue zip code analysis performed by 3rd party
© 2023 Orthofix Medical Inc. All rights reserved | 16
ORTHOFIX®Ⓡ
SeaSpine.View entire presentation